Solid lipid nanoparticles for nose to brain delivery of haloperidol: In vitro drug release and pharmacokinetics evaluation

Acta Pharmaceutica Sinica B

Volumn 4, Issue 6, 2014, Pages 454-463

  Yasir, Mohd ^a,b   Sara, Udai Vir Singh ^c  

^a UTTARAKHAND TECHNICAL UNIVERSITY   (India)

^b ITS Paramedical College (Pharmacy)   (India)

^c RAJ KUMAR GOEL INSTITUTE OF TECHNOLOGY   (India)

Author keywords

Brain targeting; Haloperidol; Intranasal route; Pharmacokinetics; Solid lipid nanoparticles

Indexed keywords

GLYCEROL BEHENATE; GLYCEROL PALMITOSTEARATE; GLYCEROL STEARATE; HALOPERIDOL; PALMITIC ACID; SOLID LIPID NANOPARTICLE; STEARIC ACID;

ADULT; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DIFFUSION; DIRECT TRANSPORT PERCENTAGE; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG ENTRAPMENT EFFICIENCY; DRUG FORMULATION; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; DRUG STRUCTURE; DRUG TARGETING; DRUG UPTAKE; EMULSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NONHUMAN; PARTICLE SIZE; PHARMACOLOGICAL PARAMETERS; PROCESS OPTIMIZATION; RAT; SUSTAINED DRUG RELEASE; TIME TO MAXIMUM PLASMA CONCENTRATION; WISTAR RAT; X RAY DIFFRACTION; ZETA POTENTIAL;

EID: 84989321554     PISSN: 22113835     EISSN: 22113843     Source Type: Journal    
DOI: 10.1016/j.apsb.2014.10.005     Document Type: Article

References (48)

1. Kingsley J.D., Dou H.Y., Morehead J., Rabinow B., Gendelman H.E., Destache C.J. Nanotechnology: a focus on nanoparticles as a drug delivery system. J Neuroimmune Pharmacol 2006, 1:340-350.
2. Falzarano M.S., Passarelli C., Bassi E., Fabris M., Perrone D., Sabatelli P., et al. Biodistribution and molecular studies on orally administered nanoparticle-AON complexes encapsulated with alginate aiming at inducing dystrophin rescue in mdx mice. BioMed Res Int 2013, 2013:527418.
3. Sahoo S.K., Labhasetwar V. Nanoparticles interface: an important determinant in nanoparticle-mediated drug/gene delivery. Nanoparticle technology for drug delivery 2006, 139-154. Taylor & Francis, NY, USA, New York. R.B. Gupta, U.B. Kompella (Eds.).
4. Misra A., Ganesh S., Shahiwala A., Shah S.P. Drug delivery to the central nervous system: a review. J Pharm Pharm Sci 2003, 6:252-273.
5. Alam M.I., Baboota S., Ahuja A., Ali M., Ali J., Sahni J.K., et al. Pharmacoscintigraphic evaluation of potential of lipid nanocarriers for nose-to-brain delivery of antidepressant drug. Int J Pharm 2014, 470:99-106.
6. Illum L. Nasal drug delivery: new developments and strategies. Drug Discov Today 2002, 7:1184-1189.
7. Krishnamoorthy R., Mitra A.K. Prodrugs for nasal drug delivery. Adv Drug Deliv Rev 1998, 29:135-146.
8. Haque S., Md S., Sahni J.K., Ali J., Baboota S. Development and evaluation of brain targeted intranasal alginate nanoparticles for treatment of depression. J Psychiatr Res 2014, 48:1-12.
9. Benvegnú D.M., Barcelos R.C., Boufleur N., Reckziegel P., Pase C.S., Ourique A.F., et al. Haloperidol-loaded polysorbate-coated polymeric nanocapsules increase its efficacy in the antipsychotic treatment in rats. Eur J Pharm Biopharm 2011, 77:332-336.
10. Yasir M., Sara U.V.S. Development and validation of UV spectrophotometric method for the estimation of haloperidol. Br J Pharm Res 2014, 4:1407-1415.
11. Settle E.C., Ayd F.J. Haloperidol: a quarter century of experience. J Clin Psychiatry 1983, 44:440-448.
12. Forsman A.O. Individual variability in response to haloperidol. Proc Roy Soc Med 1976, 69 (Suppl 1):S9-S13.
13. Vella-Brincat J., Macleod A.D. Haloperidol in palliative care. Palliat Med 2004, 18:195-201.
14. Chang W.H., Lam Y.W.F., Jann M.W., Chen H. Pharmacokinetics of haloperidol and reduced haloperidol in chinese schizophrenic patients after intravenous and oral administration of haloperidol. Psychopharmacology 1992, 106:517-522.
15. Budhian A., Siegel S.J., Winey K.I. Haloperidol-loaded PLGA nanoparticles: systematic study of particle size and drug content. Int J Pharm 2007, 336:367-375.
16. Hollister L.E. Basic and Clinical Pharmacology 1995, Prentice Hall, London. 6th ed.
17. Kaur I.P., Bhandari R., Bhandari S., Kakkar V. Potential of solid lipid nanoparticles in brain targeting. J Control Release 2008, 127:97-109.
18. Schwarz C., Mehnert W., Lucks J.S., Muller R.H. Solid lipid nanoparticles (SLN) for controlled drug delivery. I. production, characterization and sterilization. J Control Release 1994, 30:83-96.
19. Yasir M., Sara U.V.S. Preparation and optimization of haloperidol loaded solid lipid nanoparticles by box-behnken design. J Pharm Res 2013, 7:551-558.
20. Helgason T., Awad T.S., Kristbergsson K., McClements D.J., Weiss J. Effect of surfactant surface coverage on formation of solid lipid nanoparticles (SLN). J Colloid Interface Sci 2009, 334:75-81.
21. Kumar R., Yasir M., Saraf S.A., Gaur P.K., Kumar Y., Singh A.P. Glyceryl monostearate based nanoparticles of mefenamic acid: fabrication and in vitro characterization. Drug Invention Today 2013, 5:246-250.
22. Shah K.A., Date A.A., Joshi M.D., Patravale V.B. Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery. Int J Pharm 2007, 345:163-171.
23. Singh A.P., Saraf S.K., Saraf S.A. SLN approach for nose-to-brain delivery of alprazolam. Drug Deliv Transl Res 2012, 2:498-507.
24. Serralheiro A., Alves G., Fortuna A., Falcão A. Intranasal administration of carbamazepine to mice: a direct delivery pathway for brain targeting. Eur J Pharm Sci 2014, 60:32-39.
25. Trotta M., Debernardi F., Caputo O. Preparation of solid lipid nanoparticles by a solvent emulsification-diffusion technique. Int J Pharm 2003, 257:153-160.
26. Jores K., Mehnert W., Drechsler M., Bunjes H., Johann C., Mäder K. Investigations on the structure of solid lipid nanoparticles (SLN) and oil-loaded solid lipid nanoparticles by photon correlation spectroscopy, field-flow fractionation and transmission electron microscopy. J Control Release 2004, 95:217-227.
27. Venkateswarlu V., Manjunath K. Preparation, characterization and in vitro release kinetics of clozapine solid lipid nanoparticles. J Control Release 2004, 95:627-638.
28. Varshosaz J., Tabbakhian M., Mohammadi M.Y. Formulation and optimization of solid lipid nanoparticles of buspirone HCl for enhancement of its oral bioavailability. J Liposome Res 2010, 20:286-296.
29. Tamjidi F, Shahedi M, Varshosaz J, Nasirpour A. Design and characterization of astaxanthin-loaded nanostructured lipid carriers. Innov Food Sci Emerg Technol 2 July 2014. Available from: , in press. http://dx.doi.org/10.1016/j.ifset.2014.06.012.
30. Chadha R., Bhandari S. Drug-excipient compatibility screening-role of thermoanalytical and spectroscopic techniques. J Pharm Biomed Anal 2014, 87:82-97.
31. Chen D.B., Yang T.Z., Lu W.L., Zhang Q. In vitro and in vivo study of two types of long-circulating solid lipid nanoparticles containing paclitaxel. Chem Pharm Bullo 2001, 49:1444-1447.
32. Korsmeyer R.W., Gurny R., Doelker E., Buri P., Peppas N.A. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm 1983, 15:25-35.
33. Higuchi T. Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci 1963, 52:1145-1149.
34. Souto E.B., Wissing S.A., Barbosa C.M., Müller R.H. Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int J Pharm 2004, 278:71-77.
35. Ghosh M.N. Fundamentals of experimental pharmacology 2005, Kolkata: Hilton & Company, West Bengal, India. 3rd ed.
36. Kumar M., Misra A., Babbar A.K., Mishra A.K., Mishra P., Pathak K. Intranasal nanoemulsion based brain targeting drug delivery system of risperidone. Int J Pharm 2008, 358:285-291.
37. Fazil M., Md S., Haque S., Kumar M., Baboota S., Sahni J.K., et al. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur J Pharm Sci 2012, 47:6-15.
38. Haque S., Md S., Fazil M., Kumar M., Sahni J.K., Ali J., et al. Venlafaxine loaded chitosan NPs for brain targeting: pharmacokinetic and pharmacodynamic evaluation. Carbohydr Polym 2012, 89:72-79.
39. Jain T., Bhandari A., Ram V., Sharma S., Chaudhary R.K., Parakh M. High-performance liquid chromatographic method with diode array detection for quantification of haloperidol levels in schizophrenic patients during Routine clinical practice. J Bioanal Biomed 2011, 3:8-12.
40. Rahman N., Khatoon A., Rahman H. Studies on the development of spectrophotometric method for the determination of haloperidol in pharmaceutical preparation. Quím Nova 2012, 35:392-397.
41. Md S., Khan R.A., Mustafa G., Chuttani K., Baboota S., Sahni J.K., et al. Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model. Eur J Pharm Sci 2013, 48:393-405.
42. Müller R.H., Mäder K., Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm 2000, 50:161-177.
43. Janicki C.A., Ko C.T. Haperidol. Analytical profile of drug substances 1991, 9th:342-344. Academic Press, New York.
44. Sanjula B., Shah F.M., Javed A., Alka A. Effect of poloxamer 188 on lymphatic uptake of carvedilol-loaded solid lipid nanoparticles for bioavailability enhancement. J Drug Target 2009, 17:249-256.
45. Bunjes H., Unruh T. Characterization of lipid nanoparticles by differential scanning calorimetry, X-ray and neutron scattering. Adv Drug Deliv Rev 2007, 59:379-402.
46. Khan S., Patil K., Bobade N., Yeole P., Gaikwad R. Formulation of intranasal mucoadhesive temperature-mediated in situ gel containing ropinirole and evaluation of brain targeting efficiency in rats. J Drug Target 2010, 18:223-234.
47. Al-Ghananeem A.M., Saeed H., Florence R., Yokel R.A., Malkawi A.H. Intranasal drug delivery of didanosine-loaded chitosan nanoparticles for brain targeting: an attractive route against infections caused by aids viruses. J Drug Target 2010, 18:381-388.
48. Zhang Q.Z., Jiang X.G., Jiang W.M., Lu W., Su L.N., Shi Z.Q. Preparation of nimodipine-loaded microemulsion for intranasal delivery and evaluation on the targeting efficiency to the brain. Int J Pharm 2004, 275:85-96.